Клопидогрель и предотвращение тромботических осложнений атеросклероза: стоимость таблеток или эффективность затрат?
Abstract
Одним из серьезных ограничений для широкого внедрения клопидогрела в клиническую практику является относительно высокая стоимость препарата. Своего рода противостояние между серьезной доказательной базой и ценой клопидогреля стало поводом для оценки экономической целесообразности его использования. Подобная оценка, в основном с расчетом коэффициента 'затраты/эффективность', выполнена во многих странах для большинства состояний, при которых клопидогрел был эффективен в крупных клинических исследованиях.
References
1. Mark D.B., Hlatky M.A., Califf R.M. et al. Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction. N Engl J Med. 1995; 332: 1418–1424.
2. WHO Commission on Macroeconomics and Health. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health-Geneva: WHO, 2001.
3. Murray C.J., Lauer J.A., Hutubessy R.C.W. et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular risk. Lancet (2003) 361: 717: 25.
4. Van Hout B.A., Tangelder M.J.D., Bervoets P., Gabriel S. Cost.effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke and peripheral arterial disease in The Netherlands. ISPOR Congress Barcelona, November 2003. (abstract)
5. Levy E., Gabriel S., Carita P., Dinet J. An economic evaluation of clopidogrel in secondary prevention of ischemic event: high risk population. ISPOR Congress Rotterdam, November 2002. (abstract).
6. Annemans L., Gabriel S., Spiesser J., Vranckx K., de Knock M., Carita P. An economic evaluation of clopidogrel vs aspirin in secondary prevention of ischemic events in high risk atherothrom. botic patients. ISPOR Congress Barcelona, November 2003. (abstract).
7. Muls E., Van Ganse E., Closon M.C. Cost.effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 (Suppl.): S111-S116.
8. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST.segment elevation. New Engl J Med 2001; 345: 494-502.
9. Yusuf S., Mehta S.R., Zhao F. et al. on Behalf of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) Trial Investigators. Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. Circulation 2003; 107:966-972.
10. Bertrand M.E., Simoons M.L., Fox K.A.A., Wallentin L.C., Hamm C.W., McFadden E., De Feyter P.J., Specchia G., Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST.segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. EurHeart J 2002; 23: 1809–1840.
11. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., Jones R.H., Kereiakes D., Kupersmith J., Levin T.N., Pepine C.J., Schaeffer J.W., Smith E.E III., Steward D.E., Theroux P. ACC/AHA guideline update for the management of patients with unstable angina and non–ST.segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366–74.
12. Всероссийское научное общество кардиологов. Лечение острого коронарного синдрома без стойких подъемов сегмента ST на ЭКГ. Российские рекомендации. Кардиология 2001; №10 (приложение: 1-23).
13. Lamy A., Chorlavicius S., Gafni A. et al. 'The Cost.effectiveness of the Use of Clopidogrel in Acute Coronary Syndromes based upon the CURE Study' Circulation 2002 Vol. 106(19), P. ii-758 (abstract 3721)
14. Annemans L., Lindgren P., Frej A. et al. 'Cost.Effectiveness Analysis of Clopidogrel in Acute Coronary Syndromes without ST.Segment Elevation: A 5 European Countries Analysis' European Heart Journal 2003 24 (abstract supplement).
15. van Hout B.A., Tangelder M. J.D., Bervoets P., Gabriel S. Cost.effectiveness analysis of clopidogrel in acute coronary syndromes without ST.segment elevation in the Netherlands. ISPOR Congress Barcelona, November 2003. (abstract). P. 39.
16. Lindgren P., Jоnsson B., Spiesser J., Carita P., Gabriel S. Short and long.term Cost.Effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST.segment elevation in Scandinavian countries. ISPOR Congress Barcelona, November 2003. (abstract). P. 16
17. Weintraub W.S., Mahoney E.M., Lamy A., Caro J., Gabriel S., Yuan Y., Jackson J., Chen R., Yusuf S. Long –term Cost.effectiveness of platelet inhibition with clopidogrel in patients presenting with acute coronary syndromes: results from the CURE trial. ISPOR Congress Barcelona, November 2003. (abstract). P. 14
18. Mark D.B, Harrington R.A., Lincoff M. et al. Cost.Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non–ST.Elevation Acute Coronary Syndromes. Circulation 2000; 101: 366–371.
19. Mahoney E.M., Jurkovitz C.T, Chu H. et al. Cost and Cost effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non–ST Segment Elevation Myocardial Infarction. JAMA 2002; 288: 1851–1558.
20. Phillips K.A., Shlipak M.G., Coxson P. et al. Health and Economic Benefits of Increased b.Blocker Use Following Myocardial Infarction. JAMA 2000; 284: 2748–2754.
21. Mehta S., Yusuf S., Peters R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long.term therapy in patients undrgoing percutaneous coronary intervention: the PCI.CURE study. Lancet. 2001;358:527.533.
22. Mahoney E., Mehta S., Lamy A. et al. 'Long term cost effectiveness of platelet inhibition with clopidogrel in patients undergoing PCI after presenting with an acute coronary syndromes: Results from PCI.CURE trial' Circulation 2003 Supplement 4 Vol. 108(17) P. iv-576 (аbstract) 2625
23. Annemans L., Lindgren P., Frej A. et al. 'Cost.Effectiveness Analysis of Clopidogrel in Patients with Unstable Coronary Artery Disease undergoing PCI: A 5 European Countries Analysis' European Heart Journal 2003, 24 (abstract supplement)
24. Mehta S., Weintraub W., Junsson B. et al. 'Incremental Cost.Effectiveness of Early and Long Term Clopidogrel in Patients undergoing PCI in the CURE trial: The PCI.CURE Economic Analysis' The Journal of the American College of Cardiology 2003, 41(6:S2) P. 383
25. Steinhubl S.R., Berger P.B., Mann J.T. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411.2420.
26. Beinart S., Kolm P., Veledar E. et al. 'Short and Long.Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy with Clopidogrel following Percutaneous Coronary Intervention: Results from CREDO' Circulation 2003 Supplement 4 Vol. 108(17)P. iv-775 (аbstract) 3495
Review
For citations:
. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2004;(1):39-45. (In Russ.)
Views:
22257
Email this article 